Chemomab Therapeutics Ltd. (CMMB)
| Market Cap | 44.93M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -19.30M |
| Shares Out | 11.40M |
| EPS (ttm) | -1.41 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 91,795 |
| Open | 3.84 |
| Previous Close | 4.00 |
| Day's Range | 3.58 - 4.14 |
| 52-Week Range | 2.53 - 17.39 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 22.44 (+469.5%) |
| Earnings Date | Aug 12, 2022 |
About CMMB
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporat... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for CMMB stock is "Buy." The 12-month stock price forecast is 22.44, which is an increase of 469.54% from the latest price.
News
Chemomab Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update
─Chemomab to Host Webcast and Conference Call for Investors Today, August 12 at 8:00 am ET ─ TEL AVIV, Israel , Aug. 12, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage...
Chemomab Adds Highly Experienced Executives Further Strengthening Its R&D and Clinical Capabilities
─Appoints Ilan Vaknin, PhD, as Vice President of Research & Development and Christina Crater, MD, as Vice President of Clinical Development─ TEL AVIV, Israel , Aug. 12, 2022 /PRNewswire/ -- Chemomab Th...
Chemomab Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update
TEL AVIV, Israel , Aug. 1, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative thera...
Chemomab Presents Data Further Supporting the Mechanism of Action and Potential Efficacy of CM-101 in Primary Scleros...
—Data Presented at 2022 EASL International Liver ConferenceTM and First International Extracellular Matrix Pharmacology Congress — TEL AVIV, Israel , June 27, 2022 /PRNewswire/ -- Chemomab Therapeutics...
Chemomab Therapeutics Appoints Jill M. Quigley, JD, to Its Board of Directors
—Ms. Quigley's Broad Biotechnology Industry Experience Encompasses Leadership Positions in Executive Management, Operations and Legal Affairs— TEL AVIV, Israel , June 21, 2022 /PRNewswire/ -- Chemomab T...
Chemomab Therapeutics to Present at June Investor and Scientific Conferences
TEL AVIV, Israel , June 9, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative thera...
Data Supporting Role of Chemomab's Novel Therapeutic Target CCL24 in Systemic Sclerosis Presented at EULAR 2022
—Poster Presentation of Reverse Translational Study Data Using Patient Samples Supports Role of CCL24 as a Therapeutic Target for Systemic Sclerosis— —Chemomab's CCL24-Neutralizing Antibody CM-101 Is Ex...
Chemomab Therapeutics to Participate in H.C. Wainwright Global Investment Conference
TEL AVIV, Israel , May 18, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative thera...
Chemomab Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update
-- Company to Host Conference Call for Investors Today, May 12 at 8:00 am ET -- TEL AVIV, Israel , May 12, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotechnolo...
Chemomab Therapeutics to Report First Quarter 2022 Financial Results and Provide a Business Update
TEL AVIV, Israel , May 4, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therap...
Chemomab Therapeutics to Participate in Cantor Fitzgerald Rare Orphan Disease Summit
TEL AVIV, Israel , March 23, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative the...
New Strong Sell Stocks for March 14th
AVYA, BGS, and CMMB have been added to the Zacks Rank #5 (Strong Sell) List on March 14, 2022.
Chemomab Reports on Two Scientific Presentations that Support the Potential Therapeutic Utility of CM-101 in Systemic...
—Translational Study Data Presented at 7th Systemic Sclerosis World Congress Confirms CCL24 is Elevated in Diffuse Cutaneous Systemic Sclerosis Patients; High CCL24 Serum Levels in Patients were Correla...
Chemomab Therapeutics Announces Fourth Quarter and Year End 2021 Financial Results and Provides a Corporate Update
TEL AVIV, Israel, March 9, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for...
Chemomab Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Business Update
TEL AVIV, Israel, March 2, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative thera...
Chemomab Therapeutics to Present at Aegis Virtual Conference
TEL AVIV, Israel, Feb. 10, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative thera...
Chemomab Therapeutics Names Jack Lawler Vice President of Global Clinical Development Operations
TEL AVIV, Israel, Jan. 4, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therap...
Chemomab to Participate in LifeSci Partners Annual Corporate Access Event and H.C. Wainwright BioConnect 2022 Healthc...
TEL AVIV, Israel, Dec. 20, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative thera...
Chemomab Therapeutics Announces Expected Appointment of Dale R. Pfost as Chairman of the Board
TEL AVIV, Israel, Dec. 16, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab) a clinical-stage biotechnology company focused on the discovery and development of innovative therap...
Chemomab Therapeutics Names David M. Weiner, MD as Interim Chief Medical Officer
TEL AVIV, Israel, Dec. 3, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd. (NASDAQ: CMMB), (Chemomab) a clinical-stage biotech company focused on the discovery and development of innovative therapeutics ...
Chemomab Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Corporate Update
TEL AVIV, Israel, Nov. 12, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotech company focused on the discovery and development of innovative therapeutic...
Chemomab Announces Poster Presentation at AASLD's The Liver Meeting® 2021
TEL AVIV, Israel, Nov. 10, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotech company focused on the discovery and development of innovative therapeutic...
Chemomab to Present at Stifel 2021 Virtual Healthcare Conference
TEL AVIV, Israel, Nov. 9, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics...
Chemomab Therapeutics Names Donald R. Marvin Chief Financial Officer, Executive Vice President and Chief Operating Of...
TEL AVIV, Israel, Nov. 8, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab) a clinical-stage biotech company focused on the discovery and development of innovative therapeutics ...
Chemomab Therapeutics Hosting Key Opinion Leader Webinar on Systemic Sclerosis
TEL AVIV, Israel, Oct. 26, 2021 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) ("Chemomab"), a clinical-stage biotech company focused on the discovery and development of innovative therapeuti...